Chemotherapy induced Takotsubo cardiomyopathy  

作　　者：Sunny Goel Abhishek Sharma Aakash Garg Abhinav Chandra Vijay Shetty 

机构地区：[1]Department of Medicine, Maimonides Medical Center [2]Department of Internal Medicine, James J. Peters VA Medical Center, Mount Sinai School of Medicine, Bronx, NY 10468, United States

出　　处：《World Journal of Clinical Cases》2014年第10期565-568,共4页世界临床病例杂志

摘　　要：Chemotherapy has been linked with Takotsubo cardiomyopathy. Most of the literature on chemotherapy associated Takotsubo cardiomyopathy is on the drug 5-fluorouracil. In this report, we describe the case of a 55-year-old Asian male who developed Takotsubo cardiomyopathy while receiving dual chemotherapy with cytarabine and daunorubicin for acute myeloid leukemia. To our knowledge, it is the first case of Takotsubo cardiomyopathy associated with daunorubicin and/or cytarabine.Chemotherapy has been linked with Takotsubo cardiomyopathy. Most of the literature on chemotherapy associated Takotsubo cardiomyopathy is on the drug 5-fluorouracil. In this report, we describe the case of a 55-year-old Asian male who developed Takotsubo cardiomyopathy while receiving dual chemotherapy with cytarabine and daunorubicin for acute myeloid leukemia. To our knowledge, it is the first case of Takotsubo cardiomyopathy associated with daunorubicin and/or cytarabine.

关 键 词：TAKOTSUBO CARDIOMYOPATHY CHEMOTHERAPY CYTARABINE DAUNORUBICIN 

分 类 号：R542.2[医药卫生—心血管疾病]